LoadingLoadingLoading21 funds hold it.Insiders net selling.
Net selling: insiders sold $91.1M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsLast report
Aug 11, 2026
Period ending
Jun 30, 2026
Earnings per share
-$0.64 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Nov 5, 2026
EPS expected
-$0.74 to -$0.51
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Jun 30, 2026Reported Aug 11, 2026 | -$0.58est. -$0.64 | +9.56%beat | $0.00Alpha Vantage | No year-ago quarter |
| Mar 31, 2026Reported May 12, 2026 | -$0.73est. -$0.85 | +14.20%beat | $0.00Alpha Vantage | No year-ago quarter |
| Dec 31, 2025Reported Mar 30, 2026 | -$104.54est. -$18.24 | -$86.30miss | $0.00Alpha Vantage | No year-ago quarter |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $0 | $0 | $0 | $0 |
| What it spent | ||||
| Research and development | $18.1M | $18.2M | $20.9M | $18.6M |
| Sales and admin | $2.3M | $4.8M | $8.9M | $10.9M |
| Total operating expenses | $20.3M | $23.0M | $29.9M | $29.6M |
| What was left | ||||
| Operating profit | -$20.3M | -$23.0M | -$29.9M | -$29.6M |
| Interest on debt | — | $532.0K | — | — |
| Profit before tax | -$20.1M | -$21.8M | -$27.2M | -$23.5M |
| Net profit | -$20.1M | -$21.8M | -$27.2M | -$23.5M |
| EBITDA | -$19.2M | -$21.3M | -$27.2M | -$29.6M |
This stock is trending upward.
Trend
Constructive
75 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Veradermics announces phase 3 results for oral minoxidil for hair loss
BullishNov 2Veradermics, Incorporated Estimates – NYSE:MANE
NeutralOct 25Veradermics, Incorporated Common Stock (NYSE:MANE) Stock Quote
BullishOct 24Veradermics Price Target Raised to $204.00/Share From $170.00 by B. Riley Securities
BullishOct 23
